These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 19072177)

  • 1. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections.
    Guinea J; Bouza E
    Future Microbiol; 2008 Dec; 3(6):603-15. PubMed ID: 19072177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
    Seyedmousavi S; Verweij PE; Mouton JW
    Expert Rev Anti Infect Ther; 2015 Jan; 13(1):9-27. PubMed ID: 25488140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
    Chitasombat MN; Kontoyiannis DP
    Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole.
    Thompson GR; Wiederhold NP
    Mycopathologia; 2010 Nov; 170(5):291-313. PubMed ID: 20524153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.
    Rybak JM; Marx KR; Nishimoto AT; Rogers PD
    Pharmacotherapy; 2015 Nov; 35(11):1037-51. PubMed ID: 26598096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.
    Odds FC
    Curr Opin Investig Drugs; 2006 Aug; 7(8):766-72. PubMed ID: 16955689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
    Livermore J; Hope W
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isavuconazonium sulfate for the treatment of fungal infection.
    Walker RC; Zeuli JD; Temesgen Z
    Drugs Today (Barc); 2016 Jan; 52(1):7-16. PubMed ID: 26937491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New generation azole antifungals in clinical investigation.
    Girmenia C
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1279-95. PubMed ID: 19678798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
    Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
    Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
    Wilby KJ
    Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):281-290. PubMed ID: 29101732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
    Ledoux MP; Denis J; Nivoix Y; Herbrecht R
    J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
    Zheng X; Xu G; Zhu L; Fang L; Zhang Y; Ding H; Tong Y; Sun J; Huang P
    J Clin Pharmacol; 2018 Oct; 58(10):1266-1273. PubMed ID: 29762861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.
    Pfaller MA; Rhomberg PR; Castanheira M
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posaconazole: a broad-spectrum triazole antifungal.
    Torres HA; Hachem RY; Chemaly RF; Kontoyiannis DP; Raad II
    Lancet Infect Dis; 2005 Dec; 5(12):775-85. PubMed ID: 16310149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.